MarketCapExport financials
Phibro Animal Health Corporation (PAHC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Phibro Animal Health Corporation Balance Sheet 2026-2011 | PAHC
Brief overview of Phibro Animal Health Corporation's balance sheet structure
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Total assets increased by +61.8%, from $841.3 million to $1.4 billion. A CAGR near 12.8% points to substantial expansion.
Liabilities grew faster than assets: +78.4% versus +61.8%. A substantial part of expansion was externally funded.
Equity funds just 21% of assets versus 28.4% previously. The balance sheet is sensitive to weaker results.
Negative net debt of -$25.2 million means cash holdings are larger than debt obligations.
Cash equals 5% of the balance sheet, compared with 6% five periods ago. This is the readily available cushion.
Retained earnings reached $272.7 million, changing +25.1% over the period. A positive accumulated result supports equity.
Conclusion
Phibro Animal Health Corporation's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet Phibro Animal Health Corporation
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-5.45 M | -25.2 M | 219 M | 276 M | 205 M | -15.6 M | 338 M | 269 M | 283 M | 257 M | 319 M | 260 M | 278 M | 338 M | 296 M | - |
Long Term Debt |
45.4 M | 33.7 M | 282 M | 312 M | 273 M | 28 M | 368 M | 314 M | 300 M | 307 M | 350 M | 287 M | 286 M | 366 M | 345 M | - |
Long Term Debt Current |
10.6 M | 9.13 M | 7.46 M | 6.05 M | 6.05 M | 6.62 M | 6.44 M | - | - | 6.25 M | 2.8 M | 2.81 M | 2.97 M | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | 356 M | 344 M | 356 M | 411 M | 352 M | 345 M | 428 M | 403 M | - |
Total Current Liabilities |
316 M | 293 M | 204 M | 176 M | 191 M | 164 M | 157 M | 154 M | 143 M | 116 M | 109 M | 111 M | 112 M | - | - | - |
Total Liabilities |
1.12 B | 1.08 B | 726 M | 689 M | 669 M | 603 M | 596 M | 511 M | 487 M | 472 M | 520 M | 464 M | 457 M | 543 M | 529 M | - |
Deferred Revenue |
- | - | - | 370 K | 822 K | 1.56 M | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
353 M | 273 M | 244 M | 261 M | 248 M | 218 M | 183 M | 169 M | 132 M | 82.8 M | 34 M | -37 M | -97.2 M | -94.1 M | -116 M | - |
Total Assets |
1.5 B | 1.36 B | 982 M | 971 M | 932 M | 841 M | 784 M | 727 M | 672 M | 623 M | 610 M | 493 M | 472 M | 474 M | 441 M | - |
Cash and Cash Equivalents |
61.4 M | 68 M | 70.6 M | 41.3 M | 74.2 M | 50.2 M | 36.3 M | 57.6 M | 29.2 M | 56.1 M | 33.6 M | 29.2 M | 11.8 M | 27.4 M | 53.9 M | - |
Book Value |
385 M | 286 M | 257 M | 283 M | 262 M | 239 M | 188 M | 216 M | 185 M | 151 M | 90.5 M | 29.6 M | 15.1 M | -68.9 M | -88.2 M | - |
Total Shareholders Equity |
385 M | 286 M | 257 M | 283 M | 262 M | 239 M | 188 M | 216 M | 185 M | 151 M | 90.5 M | 29.6 M | 15.1 M | -68.9 M | -88.2 M | - |
All numbers in USD currency
Quarterly Balance Sheet Phibro Animal Health Corporation
| 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
33.7 M | 598 M | 604 M | 610 M | 604 M | 610 M | 623 M | 619 M | 623 M | 288 M | 298 M | 291 M | 298 M | 305 M | 277 M | 273 M | 277 M | 281 M | 273 M | 292 M | 293 M | 295 M | 297 M | 297 M | 209 M | 213 M | 218 M | 218 M | 208 M | 213 M | 218 M | 218 M | 224 M | 227 M | 230 M | 230 M | 236 M | 239 M | 242 M | 242 M | 277 M | 278 M | 278 M | 278 M | 282 M | 283 M | 284 M | 284 M | 285 M | 286 M | 286 M | 298 M | - | 332 M | 298 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.08 B | 1.08 B | 1.07 B | 1.07 B | 1.07 B | 1.07 B | 1.04 B | 1.05 B | 1.04 B | 708 M | 702 M | 709 M | 702 M | 691 M | 693 M | 693 M | 693 M | 686 M | 669 M | 649 M | 610 M | 603 M | 603 M | 603 M | 590 M | 597 M | 596 M | 596 M | 571 M | 589 M | 511 M | 511 M | 492 M | 486 M | 487 M | 487 M | 495 M | 502 M | 472 M | 472 M | 480 M | 496 M | 517 M | 517 M | 468 M | 471 M | 464 M | 464 M | 442 M | 449 M | 457 M | 457 M | - | 543 M | 543 M | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 448 K | 508 K | 448 K | 458 K | 822 K | 1.38 M | 1.68 M | 1.4 M | 1.56 M | 1.56 M | 1.87 M | 1.2 M | 1.11 M | 1.11 M | 1.08 M | 1 M | 965 K | 927 K | 1.47 M | 778 K | 508 K | 508 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
273 M | 336 M | 317 M | 294 M | 317 M | 294 M | 244 M | 260 M | 244 M | 246 M | 244 M | 248 M | 244 M | 248 M | 249 M | 254 M | 249 M | 247 M | 248 M | 245 M | 232 M | 220 M | 218 M | 218 M | 198 M | 191 M | 183 M | 183 M | 174 M | 167 M | 169 M | 169 M | 155 M | 145 M | 132 M | 132 M | 97.7 M | 94.7 M | 82.8 M | 82.8 M | 51.7 M | 42.2 M | 34 M | 34 M | 8.05 M | -18.2 M | -37 M | -37 M | -64.1 M | -78.3 M | -61.4 M | -76.8 M | - | -94.1 M | -94.1 M | - | - | - | - | - | - | - | - | - |
Total Assets |
1.36 B | 1.45 B | 1.41 B | 1.39 B | 1.41 B | 1.39 B | 1.29 B | 1.32 B | 1.29 B | 966 M | 973 M | 979 M | 973 M | 965 M | 962 M | 965 M | 962 M | 948 M | 932 M | 916 M | 849 M | 836 M | 841 M | 841 M | 804 M | 790 M | 784 M | 784 M | 788 M | 795 M | 727 M | 727 M | 697 M | 678 M | 672 M | 672 M | 663 M | 671 M | 623 M | 623 M | 592 M | 598 M | 608 M | 608 M | 521 M | 493 M | 493 M | 493 M | 468 M | 471 M | 472 M | 472 M | - | 474 M | 474 M | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
41.3 M | 54.9 M | 55.5 M | 72.8 M | 55.5 M | 72.8 M | 67.1 M | 60.4 M | 67.1 M | 51.8 M | 33 M | 50.2 M | 33 M | 43.2 M | 68.4 M | 37.2 M | 68.4 M | 76.3 M | 74.2 M | 70.7 M | 63.4 M | 41.2 M | 50.2 M | 50.2 M | 34.5 M | 31 M | 36.3 M | 31 M | 26.2 M | 54.9 M | 26.2 M | 54.9 M | 31.3 M | 25.9 M | 31.3 M | 25.9 M | 40.2 M | 62.1 M | 40.2 M | 62.1 M | 39.2 M | 37.4 M | 39.2 M | 37.4 M | 25.4 M | 31.8 M | 25.4 M | 31.8 M | 20.7 M | 19.7 M | 20.7 M | 19.7 M | 30.5 M | 36.9 M | 27.4 M | 28.3 M | - | - | 53.9 M | - | - | - | 48.6 M | - |
Book Value |
286 M | 362 M | 332 M | 312 M | 332 M | 312 M | 247 M | 266 M | 247 M | 259 M | 271 M | 270 M | 271 M | 273 M | 268 M | 272 M | 268 M | 263 M | 262 M | 267 M | 239 M | 233 M | 239 M | 239 M | 213 M | 192 M | 188 M | 188 M | 217 M | 207 M | 216 M | 216 M | 205 M | 192 M | 185 M | 185 M | 168 M | 169 M | 151 M | 151 M | 113 M | 102 M | 90.5 M | 90.5 M | 53.3 M | 22.6 M | 29.6 M | 29.6 M | 26 M | 21.6 M | 15.1 M | 15.1 M | - | -68.9 M | -68.9 M | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
283 M | 362 M | 332 M | 312 M | 332 M | 312 M | 247 M | 266 M | 247 M | 259 M | 271 M | 270 M | 271 M | 273 M | 268 M | 272 M | 268 M | 263 M | 262 M | 267 M | 239 M | 233 M | 239 M | 233 M | 213 M | 213 M | 213 M | 192 M | 217 M | 217 M | 217 M | 207 M | 205 M | 205 M | 205 M | 192 M | 168 M | 169 M | 168 M | 169 M | 113 M | 102 M | 90.5 M | 90.5 M | 53.3 M | 22.6 M | 29.6 M | 29.6 M | 26 M | 21.6 M | 26 M | 21.6 M | - | -68.9 M | -68.9 M | - | - | - | -88.2 M | - | - | - | -69.1 M | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Phibro Animal Health Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
China
Britain
Germany
